ClinicalTrials.gg
RecruitingNCT07939620Updated Nov 16, 2026

Non-inferiority Study of a Hydroxyapatite and Calcium Hypophosphite Toothpaste Compared With Two Comparator Toothpastes in Dentin Hypersensitivity

An interventional study of Toothpaste Containing 20% Hydroxyapatite and 2% Calcium Hypophosphite and Stannous Fluoride Toothpaste in Dentin Hypersensitivity, sponsored by Dr. August Wolff GmbH & Co. KG Arzneimittel. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Dr. August Wolff GmbH & Co. KG Arzneimittel · Not applicable, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 47 studies in Dentin Sensitivity with a site in Brazil — 5 open to participants now, 8 under way, 2 of them phase 3. Dentin Sensitivity · Brazil.

Planned enrollment
2nd of 46
186 · median 52
Started
2026
with 1 other
No phase
32 of 47
2 open now
Registered
47th of 47
by date
Lead sponsor
1 of 47
Dr. August Wolff GmbH & Co. KG Arzneimittel

Among the 47 studies in Dentin Sensitivity with a site in Brazil, this one is the 2nd largest by planned enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2026, is one of 32 with no phase, and was the 47th registered.

Dentin Sensitivity

290 studies on the registry are indexed under Dentin Sensitivity; 47 are open to participants now.

Browse Dentin Sensitivity studies →

Open to participants now

5 of the 47 studies in Dentin Sensitivity with a site in Brazil are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 18 Dentin Sensitivity studies recruiting now, 6 (33%) set no upper age limit and 11 (61%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Dentin Sensitivity with a site in Brazil, or all of them as a file.
02

Study summary

This single-center, randomized, double-blind, three-arm, non-inferiority clinical study will evaluate whether a toothpaste containing 20% hydroxyapatite and 2% calcium hypophosphite is clinically non-inferior to each of two active comparator toothpastes in reducing dentin hypersensitivity. One comparator contains stannous fluoride and the other contains 8% arginine. The study will also evaluate the safety and tolerability of the three toothpastes.

A total of 186 adults aged 18 to 65 years with dentin hypersensitivity will be randomly assigned in a 1:1:1 ratio to one of three treatment groups. Participants will use their assigned toothpaste twice daily for 56 days.

The primary outcome is the mean reduction in dentin hypersensitivity symptoms from baseline to Day 56, as measured by the airblast test score using a 0-to-100 mm visual analogue scale (VAS), comparing the test group separately with each of the two control groups.

Additional assessments include responses to the airblast and cold-water tests after the first toothpaste use and during follow-up, participants' subjective assessments of dentin sensitivity, adverse events, and investigator- and participant-rated efficacy and tolerability.

Read the detailed description

Only the main outcome measures and the main inclusion and exclusion criteria are listed in this record. Further secondary and exploratory endpoints as well as the complete eligibility criteria are specified in the study protocol.

03

Conditions studied

  • Dentin Hypersensitivity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged between 18 and 65 years.
  • Presenting with dentin .
  • At least one eligible tooth (incisor, canine, premolar, or first molar) must have visibly exposed cervical dentin on the facial surface and a score at least 30 mm on the 100-mm VAS immediately after the airblast test (VAS: 0 mm: no sensitivity; 100 mm: worst imaginable sensitivity)
  • Proper periodontal health (i.e. no probing depth > 4 mm, or other conditions that might explain their apparent dentin hypersensitivity
  • To be in good general health, as assessed by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Previous professional desensitizing treatment within the past 3 months (e.g., in-office fluoride varnish, laser desensitization)
  • Use of over-the-counter desensitizing products within the previous 8 weeks
  • Medical histories made remarkable by chronic use of antibiotics, anti-inflammatory, analgesic, anticonvulsant, sedative, and psychotropic drugs; or ongoing active treatment with any of these drug classes at the time of screening
  • Pregnancy and breastfeeding
  • Allergies and idiosyncratic responses to product ingredients (e.g., any ingredient of the or comparator products)
  • Teeth or periodontium with pathology or defects likely to cause pain (e.g., periodontal abscess, tooth mobility greater than Grade 1) (applies to teeth designated for sensitivity assessment)

Only the main eligibility criteria are listed. The complete criteria are specified in the study protocol.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
186 participants (estimated)

Study arms

  • Experimental
    20% Hydroxyapatite and 2% Calcium Hypophosphite Toothpaste

    Other: Toothpaste Containing 20% Hydroxyapatite and 2% Calcium Hypophosphite

  • Active comparator
    Stannous Fluoride Toothpaste

    Device: Stannous Fluoride Toothpaste

  • Active comparator
    8% Arginine Toothpaste

    Device: 8% Arginine Toothpaste

Interventions

  • OtherToothpaste Containing 20% Hydroxyapatite and 2% Calcium Hypophosphite

    Participants will use the assigned toothpaste twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home.

  • DeviceStannous Fluoride Toothpaste

    Participants will use a comparator toothpaste containing stannous fluoride, providing 1100 ppm fluoride, twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home.

  • Device8% Arginine Toothpaste

    Participants will use a comparator toothpaste containing 8% arginine twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home.

06

What researchers measure

Primary outcomes

  1. Mean reduction in dentin hypersensitivity symptoms, as measured by the airblast test score (rated on a visual analogue scale, VAS [0-100]) from Baseline to Day 56

    The primary endpoint is the mean reduction in dentin hypersensitivity symptoms, as measured by the airblast test score (rated on a visual analogue scale, VAS \[0-100\]) from Baseline to Day 56 between the test group and both control groups. VAS: 0 mm: No sensitivity; 100 mm: worst imaginable sensitivity. Non-inferiority will be assessed separately for the investigational toothpaste versus each of the two comparator toothpastes, using a predefined non-inferiority margin (δ) of 10 mm on the VAS scale (0-100 mm).

    Time frame: Baseline (Day 1) to Day 56 (±3 Days)

Secondary outcomes

  1. Mean change in VAS (Cold Water Test) from Baseline to Day 56

    Mean change in VAS (Cold Water Test) from Baseline to Day 56 between the test group and each of the two control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity).

    Time frame: Baseline (Day 1) to Day 56 (±3 Days)

  2. Mean change in VAS (Airblast test) from Baseline to Day 28

    Mean change in VAS (Airblast test) from Baseline to Day 28 between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity).

    Time frame: Baseline (Day 1) to Day 28 (±3 Days)

  3. Mean change in VAS (Airblast test) from Baseline to Day 1 directly after the first application

    Mean change in VAS (Airblast test) from Baseline to Day 1 directly after the first application between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity).

    Time frame: Day 1 (Baseline and directly after the first application)

  4. Mean change in VAS (Cold Water test) from Baseline to Day 28

    Mean change in VAS (Cold Water Test) from Baseline to Day 28 between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity).

    Time frame: Baseline (Day 1) to Day 28 (±3 Days)

  5. Mean change in VAS (Cold Water test) from Baseline to Day 1 directly after the first application

    Mean change in VAS (Cold Water Test) from Baseline to Day 1 directly after the first application between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity).

    Time frame: Day 1 (Baseline and directly after the first application)

07

Study locations

1 of 1 sites recruiting
  • Kosmoscience
    São Paulo, Valinhos 13270-180, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — All data and information retrieved within the investigation are an intellectual property of the Sponsor.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Jan 2027, 2 months after the start.

Of 33 industry-sponsored interventional studies with no phase under Dentin Sensitivity, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 6. This study's planned 2 months is below that.

Counting every sponsor, half of 144 studies reached it within 6 months; a quarter within 3 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartActual
Nov 9, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Feb 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939620
Lead sponsor
Dr. August Wolff GmbH & Co. KG Arzneimittel
Collaborators
Kosmoscience Ciência e Tecnologia Cosmética Ltda
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 9, 2026
Primary completion
Jan 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Anastasia Harder
Contact
anastasia.harder@drwolffgroup.com
+49521-8808-538
Ana Lúcia Tabarini Alves Pinheiro, MD
principal investigator · Kosmoscience Ciência e Tecnologia Cosmética, Importação e Exportação Ltda.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion